JP2020516689A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516689A5
JP2020516689A5 JP2020506132A JP2020506132A JP2020516689A5 JP 2020516689 A5 JP2020516689 A5 JP 2020516689A5 JP 2020506132 A JP2020506132 A JP 2020506132A JP 2020506132 A JP2020506132 A JP 2020506132A JP 2020516689 A5 JP2020516689 A5 JP 2020516689A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
composition according
solvate
pazopanib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020506132A
Other languages
English (en)
Japanese (ja)
Other versions
JP7108018B2 (ja
JP2020516689A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027980 external-priority patent/WO2018195084A1/en
Publication of JP2020516689A publication Critical patent/JP2020516689A/ja
Publication of JP2020516689A5 publication Critical patent/JP2020516689A5/ja
Application granted granted Critical
Publication of JP7108018B2 publication Critical patent/JP7108018B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020506132A 2017-04-17 2018-04-17 急性肺傷害を処置または予防する化合物、組成物および方法 Active JP7108018B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762486232P 2017-04-17 2017-04-17
US62/486,232 2017-04-17
PCT/US2018/027980 WO2018195084A1 (en) 2017-04-17 2018-04-17 Compounds, compositions and methods of treating or preventing acute lung injury

Publications (3)

Publication Number Publication Date
JP2020516689A JP2020516689A (ja) 2020-06-11
JP2020516689A5 true JP2020516689A5 (cg-RX-API-DMAC10.html) 2021-05-06
JP7108018B2 JP7108018B2 (ja) 2022-07-27

Family

ID=63856399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020506132A Active JP7108018B2 (ja) 2017-04-17 2018-04-17 急性肺傷害を処置または予防する化合物、組成物および方法

Country Status (7)

Country Link
US (3) US11166953B2 (cg-RX-API-DMAC10.html)
EP (1) EP3612184B1 (cg-RX-API-DMAC10.html)
JP (1) JP7108018B2 (cg-RX-API-DMAC10.html)
CN (1) CN110753546B (cg-RX-API-DMAC10.html)
CA (1) CA3060247A1 (cg-RX-API-DMAC10.html)
IL (1) IL270070B2 (cg-RX-API-DMAC10.html)
WO (1) WO2018195084A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
JP2023502252A (ja) * 2019-11-20 2023-01-23 イエール ユニバーシティ 虚血再灌流傷害および／または肺傷害を処置するための化合物、組成物および方法
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
US11304947B2 (en) 2020-05-22 2022-04-19 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with SARS-COV-2 infections
CN113624978B (zh) * 2021-04-06 2023-09-19 四川大学华西医院 通过检测肺泡灌洗液及血清白蛋白来评估急性呼吸窘迫综合征/急性肺损伤及预后的试剂盒

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2008080153A2 (en) * 2006-12-22 2008-07-03 The Children's Hospital Of Philadelphia A novel protein kinase c therapy for the treatment of acute lung injury
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
CA2753844A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
JP5823672B2 (ja) 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2012068487A1 (en) * 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
MX352844B (es) * 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
TWI557121B (zh) 2011-04-21 2016-11-11 原真股份有限公司 新穎激酶抑制劑
WO2013066616A1 (en) * 2011-10-31 2013-05-10 Glaxo Wellcome Manufacturing Pte Ltd Pazopanib formulation
TW201333039A (zh) 2011-12-30 2013-08-16 Abbvie Inc 雙可變域免疫球蛋白及其用途
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
EP3046909A4 (en) 2013-09-17 2017-03-29 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
EP3052480B1 (en) * 2013-09-30 2020-11-11 The Texas A & M University System Compositions associated with and methods of managing neutrophil movement
WO2015111947A1 (en) * 2014-01-24 2015-07-30 Lg Life Sciences Ltd. Composition for preventing or treating acute lung injury and acute respiratory distress syndrome
WO2015164161A1 (en) * 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
KR20170040798A (ko) 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法

Similar Documents

Publication Publication Date Title
HRP20130052T1 (hr) Lijeäśenje respiratorne bolesti
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
NO20061254L (no) Farmasoytiske blandinger
JP2023522010A5 (cg-RX-API-DMAC10.html)
JPH0648958A (ja) 吸入による非ステロイド系抗炎症剤の抗反応抗喘息活性
JP2010518122A5 (cg-RX-API-DMAC10.html)
CA2733294A1 (en) Pharmaceutical combination of a tiotropium salt and ciclesonide
RU2001119990A (ru) Применение антагониста AT-1 или модулятора рецептора АТ-2 для лечения болезней, связанных с увеличением содержания рецепторов АТ-1 или АТ-2
JP2005519891A5 (cg-RX-API-DMAC10.html)
RU2006132036A (ru) Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
JP2019536812A5 (cg-RX-API-DMAC10.html)
EP2251016B1 (en) Topical use of hyaluronic acid with filmogenic action for the treatment and prophylaxys of pathologies of the respiratory tract.
RU2003131178A (ru) Агонисты никотиновых рецепторов для лечения воспалительных заболеваний
JP2008013542A (ja) 去痰又は気道杯細胞過形成抑制のための医薬組成物
JP2007528409A5 (cg-RX-API-DMAC10.html)
HRP20120286T1 (hr) Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
JP2008533072A5 (cg-RX-API-DMAC10.html)
JP2011521982A (ja) 上気道の疾患およびインフルエンザ症候群を治療するための組成物
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
JP2008115167A (ja) トラネキサム酸を含有する気道杯細胞過形成抑制剤
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
WO2005110052A3 (en) The use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
IL275764B2 (en) Compositions and methods for the treatment of lung emphysema and other forms of copd